- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03942367
Evaluation of the Safety and Effectiveness of the vPatch Device
Evaluation of the Safety and Effectiveness of the vPatch Device for the Management and Treatment of Premature Ejaculation
Multi-center, international, prospective, randomized, double-blind, two-arms, sham-controlled, first-in-human clinical investigation.
The Patients will be allocated to one of the following groups:
- Group A (Active Device Group): Patients will receive a fully functioning vPatch device, pre-configured to deliver stimulation intensity according to the subjective motor threshold intensity reported by the Patients. Pre-configured stimulation intensity cannot be changed by the Patient.
- Group B (Sham Device Group): Patients will receive a vPatch device pre-configured to deliver the sensory electrical stimulation according to the subjective sensory threshold that is ineffective for muscle activation. Pre-configured stimulation intensity cannot be changed by the Patient.
The study will start with a Screening Visit (Visit 1), when potential Patients complaining of PE will be informed about the investigation and its objectives. If they agree to participate, after signing a valid Informed Consent Form they will undergo a full medical history and physical examination and will be selected according to eligibility criteria except IELT (which will be examined at the next visit).
The primary objective of this study is to assess the safety profile of the vPatch device and its effectiveness in delaying ejaculation when used in Patients suffering of PE.
The secondary objectives of this study are:
- To assess the Patient's perception of the ease of use of the vPatch device and treatment, through the use of a dedicated questionnaire (Usability Questionnaire).
- To assess the Patient's perception of the changes in his Premature Ejaculation Profile (PEP) under different aspects with the use of device, through the use of a dedicated questionnaire (Control and Distress Domains of the Premature Ejaculation Profile (PEP) Questionnaire).
- To assess the Patient's perceived intensity of orgasm by using the vPatch device, through the use of a validated tool (Orgasmometer).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After the first visit the Patients will undergo a run-in Home Phase, during which they will be asked to have 4 sexual intercourse sessions with their female partners, in the privacy of their home, during which their partner will measure their intravaginal ejaculatory latency time (IELT) using a stopwatch.
After the run-in Home Phase the Patients will be requested to attend to the hospital (Visit 2) and the ones with a IELT value confirming their eligibility will be randomized in the trial (otherwise they will be excluded as Screening Failures).
Visit 2 will include three steps. Step 1: conditioning stimulation, delivered to the Patient's forearm muscles, aiming at familiarizing and adapting the Patient to transcutaneous electrical stimulation. Stimulation during Step 1 will be delivered using a CE approved TensMed S82 device. Following the conditioning stimulation, the Patient will undergo Step 2: incrementally increasing perineal stimulation, in order to identify the electrical intensity of his sensory and motor activation. The Patient will recognize motor activation as a muscle contraction, similarly to the voluntary induced muscle contraction when delaying urination. Step 2 will be repeated twice. Finally, the Patient will undergo Step 3: 10 to 15 minutes (according to Investigator's discretion) of continuous functional intensity stimulation, delivered to the Patient's perineum, aiming at demonstrating safety of prolonged stimulation. Stimulation during Steps 2 and 3 will be delivered using the investigational BLE (Bluetooth Low Energy)-enabled vPatch device. Furthermore, the Investigator will carefully instruct the Patient how to safely place the device, how to safely use of the device, and how to remove the device. During this visit the baseline assessments (see flow chart) will be carried out.
Following the Visit 2, the Home Phase will initiate, where the Patients will be asked to have 4 sexual intercourse sessions with their female partners, in the privacy of their home, during which their partner will measure their Intravaginal Ejaculatory Latency Time (IELT) using a stopwatch. The 4 sessions will include four IELT measurements, while the investigational BLE-disabled vPatch device is applied, pre-configured either delivering a functional stimulation to 40 Patients (Active Device Group) or sensory stimulation to 20 Patients (Sham Device Group). All Patients will be informed that the stimulation is not necessarily detectable. The Investigator will call the Patients every day during the first three days of the Home Phase to monitor the progression and to remind to fill in the 72 h Safety Questionnaire.
The Patients will be requested to return to the site (Visit 3) after 4 intercourse sessions with their female partners in order to undergo the assessments foreseen by protocol (see flow chart) and to return the filled questionnaires and the used device. This will be considered the End of Trial Visit.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Haifa, Israel, 3109601
- Sexual Dysfunction Clinic, Rambam Medical Center
-
-
-
-
-
Napoli, Italy, 80131
- U.O.C. Urologia e Centro di litotrissia urinaria D.A.I. Nefrologia, urologia e chirurgia generale e dei trapianti di rene, anestesia e rianimazione, A.O.U. "Federico II" di Napoli
-
-
Firenze
-
Sesto Fiorentino, Firenze, Italy, 50019
- Urologia, Casa di Cura "Villa Donatello"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Male Patients, aged ≥ 18 and ≤ 60 years old.
- Patients who are diagnosed with clinical premature ejaculation or with self-perceived ELT < 3 minutes.
- Patients with stable, heterosexual, monogamous, sexual relationship for at least 3 months at the time of the enrolment.
- Patients planning to maintain the relationship for the whole duration of the study.
- Patients with 75% of IELT baseline measurement < 2 minutes and 25% of IELT baseline measurement < 3 minutes at Visit 2.
- Patients with PEDT (Premature Ejaculation Diagnostic Tool) measurement ≥ 11 at the time of enrolment.
- Patients with IIEF-5 (International Index of Erectile Function) measurement ≥ 22 at the time of enrolment.
- Patients understanding the nature of the study and providing their informed consent to participation.
- Patients willing and able to attend the follow-up visits and procedures foreseen by study protocol.
EXCLUSION CRITERIA:
- Patients with history of cardiovascular disorders.
- Patients with history of other sexual dysfunction (other than PE).
- Patients suffering of erectile dysfunction.
- Patients carrying any type of implanted pacemaker/defibrillator.
- Patients suffering of diagnosed Diabetes Mellitus with peripheral neuropathy.
- Patients suffering of perineal dermatological diseases.
- Patients suffering of perineal skin irritation / lesions.
- Patients suffering of any psychiatric major disease (axis 1) and/or taking any relevant medications.
- Patients taking antidepressant therapy, topical anesthetic agents or sexual-related cognitive behavioral therapy within the 4 weeks before the enrolment.
- Patients with past occurrences of ejaculation before intromission.
- Patients with history of genital or anorectal neoplastic illness in the 2 years before the enrolment.
- Patients with pregnant partner.
- Patients who are participating or have participated in other clinical studies within the 30 days before the study enrolment.
- Patients with any medical incidence where the use of the device may jeopardize the Patient's safety per Investigator's discretion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A (Active Device Group)
Patients will receive a fully functioning vPatch device, pre-configured to deliver stimulation intensity according to the subjective motor threshold intensity reported by the Patients.
Pre-configured stimulation intensity cannot be changed by the Patient.
|
Electrical stimulation inducing motor response at the pelvic-floor muscles.
Stimulation will be delivered by vPatch device configured to motor intensity.
|
Sham Comparator: Group B (Sham Device Group)
Patients will receive a vPatch device pre-configured to deliver the sensory electrical stimulation according to the subjective sensory threshold that is ineffective for muscle activation.
Pre-configured stimulation intensity cannot be changed by the Patient.
|
Electrical stimulation inducing sensory response at the perineum.Stimulation will be delivered by vPatch device configured to sensory intensity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events rate during the study period. All adverse occurrences (serious/non-serious or device-related/non device-related) will be recorded prospectively, categorized and evaluated for causality using defined criteria.
Time Frame: Entire Study Period (up to 2,5 months)
|
Primary Endpoint of Safety
|
Entire Study Period (up to 2,5 months)
|
Objective: change in IELT from baseline (V2) to the end of Home Phase Visit (V3).
Time Frame: Up to 56 days
|
Primary Endpoint of Device Performance
|
Up to 56 days
|
Subjective: proportion of patients reporting an improvement according to the Clinical Global Impression of Change (CGIC) measured at V3.
Time Frame: Up to 56 days
|
Primary Endpoint of Device Performance
|
Up to 56 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Patient's subjective outcome assessment of the Premature Ejaculation Profile (PEP) from baseline (V2) to the end of Home Phase Visit (V3).
Time Frame: Up to 56 days
|
Secondary Endpoint of Device Performance
|
Up to 56 days
|
Evaluation of Patient's subjective outcome assessment of orgasmic intensity via Orgasmometer from baseline (V2) to the end of Home Phase Visit (V3).
Time Frame: Up to 56 days
|
Secondary Endpoint of Device Performance
|
Up to 56 days
|
Evaluation of Patient's subjective outcome assessment of ease of use of the vPatch device and treatment during Home Phase.
Time Frame: Entire Study Period (up to 2,5 months)
|
Secondary Endpoint of Device Performance
|
Entire Study Period (up to 2,5 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ilan Gruenwald, MD, Sexual Dysfunction Clinic, Rambam Medical Center - Haifa, Israel
Publications and helpful links
General Publications
- Althof SE. Prevalence, characteristics and implications of premature ejaculation/rapid ejaculation. J Urol. 2006 Mar;175(3 Pt 1):842-8. doi: 10.1016/S0022-5347(05)00341-1.
- Dinsmore WW, Hackett G, Goldmeier D, Waldinger M, Dean J, Wright P, Callander M, Wylie K, Novak C, Keywood C, Heath P, Wyllie M. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int. 2007 Feb;99(2):369-75. doi: 10.1111/j.1464-410X.2006.06583.x. Epub 2006 Nov 24.
- Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, Rothman M, Gagnon DD, Polverejan E; 3004 Study Group. Premature ejaculation: results from a five-country European observational study. Eur Urol. 2008 May;53(5):1048-57. doi: 10.1016/j.eururo.2007.10.015. Epub 2007 Oct 16.
- Tang WS, Khoo EM. Prevalence and correlates of premature ejaculation in a primary care setting: a preliminary cross-sectional study. J Sex Med. 2011 Jul;8(7):2071-8. doi: 10.1111/j.1743-6109.2011.02280.x. Epub 2011 Apr 14.
- Shafik A. The mechanism of ejaculation: the glans-vasal and urethromuscular reflexes. Arch Androl. 1998 Sep-Oct;41(2):71-8. doi: 10.3109/01485019808987948.
- Patrick DL, Giuliano F, Ho KF, Gagnon DD, McNulty P, Rothman M. The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice. BJU Int. 2009 Feb;103(3):358-64. doi: 10.1111/j.1464-410X.2008.08041.x. Epub 2008 Sep 12.
- Althof SE, Brock GB, Rosen RC, Rowland DL, Aquilina JW, Rothman M, Tesfaye F, Bull S. Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation. J Sex Med. 2010 Jun;7(6):2243-2252. doi: 10.1111/j.1743-6109.2010.01793.x. Epub 2010 Mar 30.
- Limoncin E, Lotti F, Rossi M, Maseroli E, Gravina GL, Ciocca G, Mollaioli D, Di Sante S, Maggi M, Lenzi A, Jannini EA. The impact of premature ejaculation on the subjective perception of orgasmic intensity: validation and standardisation of the 'Orgasmometer'. Andrology. 2016 Sep;4(5):921-6. doi: 10.1111/andr.12220. Epub 2016 May 23.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL-PR-03-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Ejaculation
-
Janssen Research & Development, LLCCompletedSexual Dysfunction, Physiological | EjaculationGermany, Spain, Portugal, Finland, Sweden, Austria
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedSexual Dysfunction | Ejaculation
-
Sohag UniversityCompletedVitamin D, Vitamin B12 and Folic Acid Among Patients With Premature EjaculationEgypt
-
PfizerCompletedEjaculationUnited States
-
Alza Corporation, DE, USACompleted
-
PfizerCompletedEjaculationUnited States, Australia, Canada, United Kingdom
-
PfizerCompletedEjaculationItaly, Spain, Australia, Austria, Canada, Czech Republic, France, Germany, Israel, Norway, Poland, Sweden, Turkey, Netherlands
-
Alza Corporation, DE, USACompleted
-
Plethora Solutions LtdCompleted
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...CompletedPremature EjaculationChina
Clinical Trials on Active Device (vPatch)
-
Cedars-Sinai Medical CenterNational Institutes of Health (NIH); Indiana UniversityRecruitingAtrial FibrillationUnited States
-
ReShape LifesciencesUnknownObesityUnited States, Australia
-
Case Western Reserve UniversityHighland Instruments, Inc.RecruitingDiabetic Neuropathies | Chronic PainUnited States
-
Neurovalens Ltd.NRI Institute of Medical SciencesRecruiting
-
Temple UniversityNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingDiarrhea | Respiratory Viral Infection | Gastrointestinal Infection | Waterborne DiseasesUnited States
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
TheranicaCompleted
-
CentraCareElectroCore INCCompletedTraumatic Brain Injury | Acute Brain InjuriesUnited States
-
ElectroCore INCCompleted
-
Assistance Publique - Hôpitaux de ParisSchwa medico (device lending)Active, not recruitingOsteoarthritis | Musculoskeletal Pain | Erosive OsteoarthritisFrance